Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06400563 · ClinicalTrials.gov registry record · NA

MRg-NIRS Imaging System Breast Cancer Trial

A NA study of Breast Cancer, sponsored by Keith D. Paulsen.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT06400563: Recruiting NA study of Breast Cancer, sponsored by Keith D. Paulsen.

NCT06400563 is a NA study of Breast Cancer that is actively recruiting participants, run by Keith D. Paulsen. The registered enrollment target is 20 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06400563, a NA study of Breast Cancer, is actively recruiting participants, sponsored by Keith D. Paulsen.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This trial is a study of 20 women with breast cancer to evaluate the addition of MR-guided (MRg) near-infrared spectroscopy (NIRS) with and without contrast, as part of a program to improve clinical management of women receiving breast magnetic resonance imaging (MRI).

Conditions Studied

Interventions

  • DEVICE MRg-NIRS

Study Locations (1)

New Hampshire

  • Dartmouth-Hitchcock Medical Center - Lebanon

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-09-23
Est. Completion 2027-03-31
Phase NA

Sponsor

Keith D. Paulsen

1 total trials

What the Registry Record Tells You About NCT06400563

The ClinicalTrials.gov registry entry for NCT06400563 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Keith D. Paulsen, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRg-NIRS is the first listed.

NCT06400563 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.

Frequently Asked Questions

What is clinical trial NCT06400563 about?

NCT06400563 is a clinical study titled "MRg-NIRS Imaging System Breast Cancer Trial". This trial is a study of 20 women with breast cancer to evaluate the addition of MR-guided (MRg) near-infrared spectroscopy (NIRS) with and without contrast, as part of a program to improve clinical management of women receiving breast magnetic resonance imaging (MRI).

What is the current status of trial NCT06400563?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-09-23. Estimated completion is 2027-03-31.

What conditions does trial NCT06400563 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT06400563?

The interventions under investigation include: MRg-NIRS (DEVICE).

Who is sponsoring clinical trial NCT06400563?

This trial is sponsored by Keith D. Paulsen, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06400563 being conducted?

This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.